Dear OncoLink "Ask The Experts,"
How is Mitoxantrone used for prostate cancer treatment?
Carolyn Vachani RN, MSN, AOCN, OncoLink's Nurse Educator, responds:
Mitoxantrone is a type of chemotherapy that is given through an IV (intravenous), typically every three weeks, when used for prostate cancer treatment. In clinical trials of men with hormone refractory prostate cancer, mitoxantrone plus prednisone resulted in improved pain control when compared to prednisone alone. Men treated with mitoxantrone had higher decreases in their PSA levels, but there was no improvement in the length of survival for the men on mitoxantrone. Mitoxantrone may be used as part of a palliative care regimen, with the goal of improving quality of life in the face of a terminal illness or as a second line chemotherapy.
Dec 7, 2010 - Nilotinib may improve survival in some chronic myeloid leukemia (CML) patients, and patients with various types of CML respond well to ponatinib, according to research being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other studies being presented outline the optimal use of imatinib, address how a new gene target functions for several myeloid malignancies, highlight a tool for predicting acute myeloid leukemia outcomes, and address the use of mitoxantrone in acute lymphoblastic leukemia.
Sep 30, 2014
Mar 17, 2010